London, UK (PRWEB) November 17, 2014
The global non-Hodgkin lymphoma (NHL) treatment market is forecast to increase from a value of USD 5.6 billion as of 2013 to USD 9.2 billion by end-2020, posting a CAGR of just under 7.5%. A high level of unmet clinical needs and the launch of promising medications, such as new small molecule inhibitors and next-gen monoclonal antibodies, are expected to drive the NHL sector’s expansion; however, the patent expiration of blockbuster Rituxan in the European Union is likely to hinder the market’s growth in the region.
Whilst Rituxan has drastically improved survival rates for NHL patients and been the standard of care in front-line therapeutic regimens as well as in maintenance settings, resistance to rituximab therapies is increasingly being observed. Bridging over rituximab resistance has been a key focus of the latest therapeutic development.
Comprehensive market research report “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options” elaborated by GBI Research is now available at MarketPublishers.com.
Title: Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
Published: October, 2014
Price: US$ 4,995.00
The report presents an all-round analysis of the NHL treatment usage patterns, market characterisation, pipeline, and key licensing and co-development deals in the 8 leading developed markets of the USA, France, the UK, Germany, Spain, Italy, Span and Canada. The study offers a brief overview of the disease, including information on etiology, pathogenesis, diagnosis and treatment algorithms. It gives a detailed analysis of currently marketed drugs used to treat NHL, investigating their efficacy, safety, treatment modes and weaknesses/strengths and including a comparison of the drugs by efficacy and safety. The study offers multi-scenario forecasts of the market till 2020, considering how the market may be influenced by new drugs’ introduction, the expiry of major patents on current drugs along with the changes in NHL epidemiology across the top developed markets.
Reasons to Buy:
- Get a clear idea of the NHL pipeline and the factors demonstrating that it is getting more innovative.
- Study detailed profiles of the most promising pipeline products, besides gaining insights into how they are set to compete in the marketplace and who their key competitors will likely be.
- Become abreast of the main trends in the size and duration of NHL clinical trials with respect to industry averages and assess the potential risk of future developmental programmes according to MoA by taking into account the recorded clinical trial failures.
- Discover how the global NHL market is set to develop through to 2020, and develop a more effective strategy via an understanding of key barriers and drivers in the sector.
More comprehensive studies by the publisher can be found at GBI Research page.